Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin
NCT03673605 · PharmEvo Pvt Ltd · PHASE4 · withdrawn · last registry update 2018-09-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No patients Enrollment” | – | Registry record, PharmEvo Pvt Ltd |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-30Phase 3 first posted: Sudeep Shivakumar, Rivaroxaban 10 MG and acetylsalicylic acid 81 mg + acetylsalicylic acid 81 mg (NCT04075240)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04067505)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04066764)
- 2019-08-05Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Antiplatelet-only strategy + Oral Anticoagulant plus background antiplatelet therapy (NCT04045665)
- 2019-07-23Phase 3 first posted: Emory University, Nuwiq (low dose protocol) + HEMLIBRA (NCT04030052)
- 2019-07-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Apixaban + Placebo (NCT04007289)
- 2019-06-25Phase 3 first posted: Imperial College London, Apixaban Oral Tablet + Dabigatran (NCT03996772)
- 2019-05-31Phase 3 first posted: The George Institute, Rivaroxaban 2.5 Mg Oral Tablet (NCT03969953)
- 2019-05-06Phase 3 first posted: Pfizer, PF-06741086 (NCT03938792)
- 2019-04-08Phase 3 first posted: Yale University, Apixaban + Aspirin (NCT03907046)
- 2019-03-04Phase 3 first posted: Pfizer, PF-06838435/ fidanacogene elaparvovec (NCT03861273)
- 2019-02-26Phase 3 first posted: Medexus Pharma, Inc., APVO101 (NCT03855280)
- 2018-12-17Phase 3 first posted: Nippon Medical School, a drug against F10 (NCT03777631)
- 2018-10-11Phase 3 first posted: Massachusetts General Hospital, Rivaroxaban + Warfarin (NCT03702582)
- 2018-10-02Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Apixaban 5 MG (NCT03692065)
- 2018-08-14Phase 3 first posted: Ottawa Heart Institute Research Corporation, Rivaroxaban 15 MG Oral Tablet [Xarelto] (NCT03630055)
- 2018-07-16Phase 3 first posted: Pfizer, Standard of Care FIX Replacement therapy + Standard of Care FVIII Replacement therapy (NCT03587116)
- 2018-06-26Phase 3 first posted: CSL Behring, AAV5-hFIXco-Padua + Factor IX (FIX) (NCT03569891)
- 2018-04-24Phase 3 first posted: Ottawa Hospital Research Institute, Rivaroxaban 10 MG (NCT03506815)
- 2018-02-09Phase 3 first posted: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Rivaroxaban + ASA (NCT03428373)
- 2017-11-14Phase 3 first posted: University of Maryland, Baltimore, Kcentra + Frozen Plasma Product, Human (NCT03341156)
- 2017-11-06Phase 3 first posted: Ottawa Heart Institute Research Corporation, Ticagrelor + Rivaroxaban (NCT03331484)
- 2017-10-20Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT03315455)
- 2017-09-18Phase 3 first posted: University Hospital, Brest, Reduced dose of DOAC + Full dose of DOAC (NCT03285438)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision